Vaxart Inc
VXRT0.320USD
0.000
Close 09/19, 16:00（ET）Quotes delayed by 15 min
73.03MMarket Cap
LossP/E TTM
More Details of Vaxart Inc Company
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its development programs include pill vaccines designed to protect against norovirus (cause for acute gastroenteritis), coronavirus, including SARS-CoV-2 (COVID-19)), and influenza. In addition, it has generated preclinical data for its therapeutic vaccine candidate targeting cervical cancer and dysplasia caused by human papillomavirus. The Company's platform technology employs a vector-based approach and consists of various components, such as a vector (adenovirus type 5 (Ad5); an antigen (Ad5 DNA); an adjuvant (Toll-like receptor 3 (TLR3)), and its proprietary enteric-coated tablet.
Company Info
Ticker SymbolVXRT
Company nameVaxart Inc
IPO dateMar 17, 1980
CEOMr. Steven (Steve) Lo
Number of employees105
Security typeOrdinary Share
Fiscal year-endMar 17
Address170 Harbor Way, Suite 300
CitySOUTH SAN FRANCISCO
Stock exchangeUS 'Other OTC' and Grey Market
CountryUnited States of America
Postal code94080
Phone16505503500
Websitehttps://vaxart.com/
Ticker SymbolVXRT
IPO dateMar 17, 1980
CEOMr. Steven (Steve) Lo
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Edward B. Berg
Mr. Edward B. Berg
Senior Vice President, General Counsel
Senior Vice President, General Counsel
435.74K
+1053.17%
Mr. Jeroen Grasman
Mr. Jeroen Grasman
Chief Financial Officer, Principal Accounting Officer and Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer and Principal Financial Officer
350.00K
--
Mr. Steven (Steve) Lo
Mr. Steven (Steve) Lo
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
140.14K
+249.14%
Dr. Elaine J. Heron, Ph.D.
Dr. Elaine J. Heron, Ph.D.
Independent Director
Independent Director
40.57K
-21.46%
Dr. Sean N. Tucker, Ph.D.
Dr. Sean N. Tucker, Ph.D.
Senior Vice President, Chief Scientific Officer
Senior Vice President, Chief Scientific Officer
--
--
Mr. W. Mark Watson
Mr. W. Mark Watson
Lead Independent Director
Lead Independent Director
--
--
Dr. James F. Cummings, M.D.
Dr. James F. Cummings, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Kevin P. Finney
Mr. Kevin P. Finney
Independent Director
Independent Director
--
--
Mr. Matt Stein
Mr. Matt Stein
IR Contact Officer
IR Contact Officer
--
--
Ms. Laurie Hastings
Ms. Laurie Hastings
Senior Vice President of Human Resources
Senior Vice President of Human Resources
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Edward B. Berg
Mr. Edward B. Berg
Senior Vice President, General Counsel
Senior Vice President, General Counsel
435.74K
+1053.17%
Mr. Jeroen Grasman
Mr. Jeroen Grasman
Chief Financial Officer, Principal Accounting Officer and Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer and Principal Financial Officer
350.00K
--
Mr. Steven (Steve) Lo
Mr. Steven (Steve) Lo
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
140.14K
+249.14%
Dr. Elaine J. Heron, Ph.D.
Dr. Elaine J. Heron, Ph.D.
Independent Director
Independent Director
40.57K
-21.46%
Dr. Sean N. Tucker, Ph.D.
Dr. Sean N. Tucker, Ph.D.
Senior Vice President, Chief Scientific Officer
Senior Vice President, Chief Scientific Officer
--
--
Mr. W. Mark Watson
Mr. W. Mark Watson
Lead Independent Director
Lead Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 23
Updated: Sat, Aug 23
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
4.55%
Geode Capital Management, L.L.C.
1.02%
BlackRock Institutional Trust Company, N.A.
0.77%
Marshall Wace LLP
0.77%
State Street Global Advisors (US)
0.37%
Other
92.52%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
4.55%
Geode Capital Management, L.L.C.
1.02%
BlackRock Institutional Trust Company, N.A.
0.77%
Marshall Wace LLP
0.77%
State Street Global Advisors (US)
0.37%
Other
92.52%
Shareholder Types
Shareholders
Proportion
Investment Advisor
6.57%
Investment Advisor/Hedge Fund
2.69%
Individual Investor
1.45%
Hedge Fund
0.42%
Research Firm
0.20%
Bank and Trust
0.04%
Family Office
0.01%
Venture Capital
0.01%
Other
88.61%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
223
30.23M
13.21%
-34.48M
2025Q1
260
32.73M
14.34%
-33.64M
2024Q4
273
38.15M
16.82%
-29.38M
2024Q3
304
39.77M
17.54%
-31.47M
2024Q2
307
43.16M
19.03%
-9.14M
2024Q1
311
42.29M
24.34%
-1.37M
2023Q4
307
17.70M
11.60%
-12.17M
2023Q3
319
19.94M
13.09%
-20.38M
2023Q2
329
30.49M
20.10%
-12.31M
2023Q1
343
36.99M
27.31%
-14.55M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
10.37M
4.54%
+291.51K
+2.89%
Mar 31, 2025
Geode Capital Management, L.L.C.
2.66M
1.17%
+58.98K
+2.27%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.78M
0.78%
-9.61K
-0.54%
Mar 31, 2025
State Street Global Advisors (US)
790.25K
0.35%
+101.40K
+14.72%
Mar 31, 2025
UBS Financial Services, Inc.
522.21K
0.23%
+63.41K
+13.82%
Mar 31, 2025
Finney Michael J
702.84K
0.31%
+16.00K
+2.33%
Jun 13, 2025
Lee (Phillip E.)
631.62K
0.28%
+397.95K
+170.31%
Mar 24, 2025
Squarepoint Capital LLP
804.48K
0.35%
+287.68K
+55.67%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
